Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 309.6 DKK 1.24%
Market Cap: 1.4T DKK

Novo Nordisk A/S
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Novo Nordisk A/S
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Cash from Operating Activities
kr123.8B
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
13%
H Lundbeck A/S
CSE:HLUN A
Cash from Operating Activities
kr3.3B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Cash from Operating Activities
kr1.5B
CAGR 3-Years
47%
CAGR 5-Years
39%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Cash from Operating Activities
-kr7.1m
CAGR 3-Years
19%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
HIDDEN
Show

See Also

What is Novo Nordisk A/S's Cash from Operating Activities?
Cash from Operating Activities
123.8B DKK

Based on the financial report for Sep 30, 2025, Novo Nordisk A/S's Cash from Operating Activities amounts to 123.8B DKK.

What is Novo Nordisk A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
13%

Over the last year, the Cash from Operating Activities growth was 5%. The average annual Cash from Operating Activities growth rates for Novo Nordisk A/S have been 22% over the past three years , 17% over the past five years , and 13% over the past ten years .

Back to Top